HC Wainwright Has Optimistic Outlook of RARE Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2025 earnings estimate for Ultragenyx Pharmaceutical to ($1.15) per share from ($1.25), maintaining a "Buy" rating with a target price of $80.00.
• Ultragenyx recently reported a quarterly earnings result of ($1.17) EPS, surpassing estimates, and observed a revenue increase of 13.2% year-over-year, totaling $166.50 million.
• Despite positive adjustments from HC Wainwright, other brokers have reduced their price targets, indicating a more cautious outlook for the stock amid various market influences.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2025 EPS estimates for shares of Ultragenyx Pharmaceutical in a report released on Wednesday, August 6th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($1.15) for the quarter, up from their previous estimate of ($1.25). HC Wainwright has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($4.85) EPS, Q1 2026 earnings at ($1.74) EPS, Q2 2026 earnings at ($1.51) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($0.99) EPS and FY2026 earnings at ($5.57) EPS.

Several other research analysts have also weighed in on the stock. Morgan Stanley reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday, July 14th. Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday. Wells Fargo & Company dropped their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. Finally, Cantor Fitzgerald dropped their target price on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Stock Up 1.4%

Ultragenyx Pharmaceutical stock traded up $0.39 during midday trading on Friday, hitting $27.78. 550,629 shares of the stock were exchanged, compared to its average volume of 1,291,107. The company has a fifty day simple moving average of $33.15 and a two-hundred day simple moving average of $36.56. Ultragenyx Pharmaceutical has a 52 week low of $25.81 and a 52 week high of $60.37. The stock has a market capitalization of $2.68 billion, a PE ratio of -5.02 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. During the same period in the prior year, the company posted ($1.52) EPS. The company's revenue was up 13.2% compared to the same quarter last year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System lifted its holdings in shares of Ultragenyx Pharmaceutical by 0.3% in the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock worth $3,284,000 after purchasing an additional 268 shares in the last quarter. GAMMA Investing LLC lifted its stake in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 323 shares in the last quarter. Xponance Inc. lifted its stake in Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after acquiring an additional 347 shares in the last quarter. BOKF NA lifted its stake in Ultragenyx Pharmaceutical by 5.0% during the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock valued at $336,000 after acquiring an additional 382 shares in the last quarter. Finally, Oak Ridge Investments LLC lifted its stake in Ultragenyx Pharmaceutical by 2.3% during the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock valued at $643,000 after acquiring an additional 395 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director owned 15,344 shares of the company's stock, valued at approximately $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.